NASDAQ:IVVD Invivyd Q2 2025 Earnings Report $0.92 -0.04 (-4.24%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.21%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Invivyd EPS ResultsActual EPS-$0.12Consensus EPS -$0.04Beat/MissMissed by -$0.08One Year Ago EPSN/AInvivyd Revenue ResultsActual Revenue$11.79 millionExpected Revenue$23.16 millionBeat/MissMissed by -$11.38 millionYoY Revenue GrowthN/AInvivyd Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time9:30AM ETUpcoming EarningsInvivyd's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Invivyd Earnings HeadlinesBTIG Research Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)September 16, 2026 | americanbankingnews.comInvivyd to Participate in Upcoming September Investor ConferencesSeptember 8, 2026 | globenewswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 23 at 1:00 AM | Weiss Ratings (Ad)Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comInvivyd Names Chairman Marc Elia CEO, Adds New DirectorsSeptember 1, 2026 | rttnews.comInvivyd Names Marc Elia CEO, Adds New Independent Director as VYD2311 Phase 3 Studies Near CompletionSeptember 1, 2026 | quiverquant.comQSee More Invivyd Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email. Email Address About InvivydInvivyd (NASDAQ:IVVD) is a biotechnology company focused on developing antibody-based medicines designed to protect against rapidly evolving viral diseases. The company uses its antibody discovery and engineering platform to create therapies intended to maintain activity as viruses mutate and to provide durable protection for people who may not be adequately protected by vaccines. Invivyd’s lead product is pemivibart, marketed in the United States as Pemgarda. Pemivibart is an intravenously administered monoclonal antibody authorized by the U.S. Food and Drug Administration for the pre-exposure prevention of COVID-19 in certain adults and adolescents who are moderately to severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination. The company continues to evaluate pemivibart and additional antibody candidates against emerging SARS-CoV-2 variants. The company was formerly known as Adagio Therapeutics and changed its name to Invivyd in 2023. Invivyd is headquartered in Waltham, Massachusetts, and its activities have primarily centered on the development and potential commercialization of antibody-based infectious-disease treatments in the United States.View Invivyd ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
